CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
软组织肉瘤中的免疫检查点抑制剂耐药
英文原题：Immune checkpoint inhibitor resistance in soft tissue sarcoma.
查看英文原题
Immune checkpoint inhibitor resistance in soft tissue sarcoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗作为癌症治疗手段的出现，极大地改变了系统性肿瘤治疗的模式。已有若干试验评估了免疫检查点阻断（ICI）在软组织肉瘤中的应用。虽然肉瘤中的总体缓解有限，但一部分患者对免疫治疗具有持久缓解。这归因于多种因素，包括组织学亚型、TIL（肿瘤浸润淋巴细胞）以及肿瘤微环境等。目前正在开展转化和临床研究，评估肉瘤中的ICI耐药性，并寻找克服这种耐药性的治疗策略。在此，我们对当前数据、提出的耐药机制以及克服这种耐药性的潜在方法进行综述。
展开英文摘要原文
The emergence of immunotherapy as a cancer therapy has dramatically changed the treatment paradigm of systemic cancer therapy. There have been several trials evaluating immune checkpoint blockade (ICI) in soft tissue sarcoma. While there is generally a limited response in sarcoma, a subset of patients has durable responses to immunotherapy.
This is attributable to a variety of factors including histologic subtype, tumor-infiltrating lymphocytes, and the tumor microenvironment among others. There is ongoing translational and clinical research evaluating ICI resistance in sarcoma and identifying therapeutic strategies to overcome this resistance.
Herein, we provide a review of the current data, proposed mechanisms of resistance, and potential approaches to overcome this resistance.
论文信息
- 作者
- Eulo V、Van Tine BA
- 第一作者单位
- Division of Medical Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.United States
- 通讯作者单位
- Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA.United States
- 文献类型
- 综述
- 期刊
- Cancer drug resistance (Alhambra, Calif.)2022
- 原文标识
- PubMed 35800372 · DOI 10.20517/cdr.2021.127
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →